Yvonne Horneffer
National Institute on Alcohol Abuse and Alcoholism(US)
Publications by Year
Research Areas
Cancer, Hypoxia, and Metabolism, Neuroblastoma Research and Treatments, Lung Cancer Research Studies, Substance Abuse Treatment and Outcomes, Glioma Diagnosis and Treatment
Most-Cited Works
- → Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis)(2017)187 cited
- → Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies(2009)122 cited
- → Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors(2011)110 cited
- → First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile(2017)46 cited
- → Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas(2011)22 cited
- → First-in-Human Phase 0 Trial of Oral 5-Iodo-2-Pyrimidinone-2′-Deoxyribose in Patients with Advanced Malignancies(2013)21 cited
- → Pharmacodynamic biomarker-driven trial of MK-2206, an AKT inhibitor, with AZD6244 (selumetinib), a MEK inhibitor, in patients with advanced colorectal carcinoma (CRC).(2012)19 cited
- → Hepatology consultation is associated with decreased early return to alcohol use after discharge from an inpatient alcohol use disorder treatment program(2024)16 cited
- → Factors underlying the neurofunctional domains of the Addictions Neuroclinical Assessment assessed by a standardized neurocognitive battery(2024)11 cited
- → Phase II trial of PF-03084014 in adults with desmoid tumors/aggressive fibromatosis.(2015)8 cited